For the process algebra, see
PEPA.
PEPA is an ampakine drug which acts as an allosteric potentiator of AMPA receptor desensitisation,[1][2] which is up to 100x more potent than aniracetam in vitro.[3] It produces memory-enhancing effects in rats when administered intravenously.[4]
[edit] References
- ^ Sekiguchi, M; Takeo, J; Harada, T; Morimoto, T; Kudo, Y; Yamashita, S; Kohsaka, S; Wada, K (1998). "Pharmacological detection of AMPA receptor heterogeneity by use of two allosteric potentiators in rat hippocampal cultures". British journal of pharmacology 123 (7): 1294–303. doi:10.1038/sj.bjp.0701707. PMC 1565288. PMID 9579722. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1565288.
- ^ Sekiguchi, M; Nishikawa, K; Aoki, S; Wada, K (2002). "A desensitization-selective potentiator of AMPA-type glutamate receptors". British journal of pharmacology 136 (7): 1033–41. doi:10.1038/sj.bjp.0704804. PMC 1573432. PMID 12145103. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1573432.
- ^ Sekiguchi, M; Fleck, MW; Mayer, ML; Takeo, J; Chiba, Y; Yamashita, S; Wada, K (1997). "A novel allosteric potentiator of AMPA receptors: 4--2-(phenylsulfonylamino)ethylthio--2,6-difluoro-phenoxyaceta mide". Journal of Neuroscience 17 (15): 5760–71. PMID 9221774.
- ^ Sekiguchi, M; Yamada, K; Jin, J; Hachitanda, M; Murata, Y; Namura, S; Kamichi, S; Kimura, I et al (2001). "The AMPA receptor allosteric potentiator PEPA ameliorates post-ischemic memory impairment". Neuroreport 12 (13): 2947–50. doi:10.1097/00001756-200109170-00038. PMID 11588608.
|
|
|
| Ionotropic |
|
|
|
|
|
|
- Agonists: Glutamate/acite site competitive agonists: Aspartate
- Glutamate
- Homoquinolinic acid
- Ibotenic acid
- NMDA
- Quinolinic acid
- Tetrazolylglycine; Glycine site agonists: ACBD
- ACPC
- ACPD
- Alanine
- CCG
- Cycloserine
- DHPG
- Fluoroalanine
- Glycine
- HA-966
- L-687,414
- Milacemide
- Sarcosine
- Serine
- Tetrazolylglycine; Polyamine site agonists: Acamprosate
- Spermidine
- Spermine
Antagonists: Competitive antagonists: AP5 (APV)
- AP7
- CGP-37849
- CGP-39551
- CGP-39653
- CGP-40116
- CGS-19755
- CPP
- LY-233,053
- LY-235,959
- LY-274,614
- MDL-100,453
- Midafotel (d-CPPene)
- NPC-12,626
- NPC-17,742
- PBPD
- PEAQX
- Perzinfotel
- PPDA
- SDZ-220581
- Selfotel; Noncompetitive antagonists: ARR-15,896
- Caroverine
- Dexanabinol
- FPL-12495
- FR-115,427
- Hodgkinsine
- Magnesium
- MDL-27,266
- NPS-1506
- Psychotridine
- Zinc; Uncompetitive pore blockers: 2-MDP
- 3-MeO-PCP
- 8A-PDHQ
- Alaproclate
- Amantadine
- Aptiganel
- ARL-12,495
- ARL-15,896-AR
- ARL-16,247
- Budipine
- Delucemine
- Dexoxadrol
- Dextrallorphan
- Dieticyclidine
- Dizocilpine
- Endopsychosin
- Esketamine
- Etoxadrol
- Eticyclidine
- Gacyclidine
- Ibogaine
- Indantadol
- Ketamine
- Ketobemidone
- Loperamide
- Memantine
- Meperidine (Pethidine)
- Methadone
- Methorphan (Dextromethorphan
- Levomethorphan)
- Methoxetamine
- Milnacipran
- Morphanol (Dextrorphan
- Levorphanol)
- NEFA
- Neramexane
- Nitrous oxide
- Noribogaine
- Orphenadrine
- PCPr
- Phencyclamine
- Phencyclidine
- Propoxyphene
- Remacemide
- Rhynchophylline
- Riluzole
- Rimantadine
- Rolicyclidine
- Sabeluzole
- Tenocyclidine
- Tiletamine
- Tramadol
- Xenon; Glycine site antagonists: ACEA-1021
- ACEA-1328
- ACPC
- Carisoprodol
- CGP-39653
- CKA
- DCKA
- Felbamate
- Gavestinel
- GV-196,771
- Kynurenic acid
- L-689,560
- L-701,324
- Lacosamide
- Licostinel
- LU-73,068
- MDL-105,519
- Meprobamate
- MRZ 2/576
- PNQX
- ZD-9379; NR2B subunit antagonists: Besonprodil
- CO-101,244 (PD-174,494)
- CP-101,606
- Eliprodil
- Haloperidol
- Ifenprodil
- Isoxsuprine
- Nylidrin
- Ro8-4304
- Ro25-6981
- Traxoprodil; Polyamine site antagonists: Arcaine
- Co 101676
- Diaminopropane
- Acamprosate
- Diethylenetriamine
- Huperzine A
- Putrescine
- Ro 25-6981; Unclassified/unsorted antagonists: Chloroform
- Diethyl ether
- Enflurane
- Ethanol (Alcohol)
- Halothane
- Isoflurane
- Methoxyflurane
- Toluene
- Trichloroethane
- Trichloroethanol
- Trichloroethylene
- Xylene
|
|
|
|
|
|
|
| Metabotropic |
|
|
Transporter
inhibitors |
|
|